Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
WHWK Whitehawk Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: WHWK
Price (delayed)
$1.72
Market cap
$81.03M
P/E Ratio
10.75
Dividend/share
N/A
EPS
$0.16
Enterprise value
-$146.54M
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is
Highlights
The company's equity has surged by 145% YoY
The company's net income has surged by 143% QoQ and by 140% YoY
Key stats
What are the main financial stats of WHWK
Market
Valuations
Earnings
Shares outstanding
47.11M
Market cap
$81.03M
Enterprise value
-$146.54M
Price to earnings (P/E)
10.75
Price to book (P/B)
0.36
Price to sales (P/S)
2.45
EV/EBIT
-5.29
EV/EBITDA
-5.17
EV/Sales
-5.28
Revenue
$27.78M
Gross profit
$24.64M
Operating income
-$63.16M
Net income
$27.61M
EBIT
$27.71M
EBITDA
$28.33M
Free cash flow
-$53.23M
Per share
Balance sheet
Liquidity
EPS
$0.16
EPS diluted
$0.15
Free cash flow per share
-$1.34
Book value per share
$4.74
Revenue per share
$0.7
TBVPS
$5.9
Total assets
$234M
Total liabilities
$12.27M
Debt
$0
Equity
$221.73M
Working capital
$220.34M
Debt to equity
0
Current ratio
18.95
Quick ratio
18.83
Net debt/EBITDA
-8.03
Margins
Efficiency
Dividend
EBITDA margin
102%
Gross margin
88.7%
Net margin
99.4%
Operating margin
-227.4%
Return on assets
22.5%
Return on equity
26.2%
Return on invested capital
111.7%
Return on capital employed
12.5%
Return on sales
99.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WHWK stock price
How has the Whitehawk Therapeutics stock price performed over time
Intraday
1.78%
1 week
1.18%
1 month
11.69%
1 year
-10.18%
YTD
-45.48%
QTD
-3.37%
Financial performance
How have Whitehawk Therapeutics's revenue and profit performed over time
Revenue
$27.78M
Gross profit
$24.64M
Operating income
-$63.16M
Net income
$27.61M
Gross margin
88.7%
Net margin
99.4%
The company's net income has surged by 143% QoQ and by 140% YoY
The net margin has soared by 141% from the previous quarter and by 134% YoY
The operating margin rose by 27% YoY and by 12% QoQ
The company's gross profit rose by 18% YoY and by 7% QoQ
Price vs fundamentals
How does WHWK's price correlate with its fundamentals
Growth
What is Whitehawk Therapeutics's growth rate over time
Valuation
What is Whitehawk Therapeutics stock price valuation
P/E
10.75
P/B
0.36
P/S
2.45
EV/EBIT
-5.29
EV/EBITDA
-5.17
EV/Sales
-5.28
The company's EPS has surged by 107% QoQ and by 106% YoY
The company's equity has surged by 145% YoY
WHWK's price to book (P/B) is 74% less than its 5-year quarterly average of 1.4 and 55% less than its last 4 quarters average of 0.8
The price to sales (P/S) is 89% less than the 5-year quarterly average of 22.9 but 2.1% more than the last 4 quarters average of 2.4
Whitehawk Therapeutics's revenue has increased by 17% YoY and by 7% from the previous quarter
Efficiency
How efficient is Whitehawk Therapeutics business performance
The return on invested capital has surged by 184% year-on-year and by 163% since the previous quarter
The return on assets has surged by 144% year-on-year and by 133% since the previous quarter
The company's return on equity has surged by 142% YoY and by 130% QoQ
The company's return on sales has surged by 141% QoQ and by 135% YoY
Dividends
What is WHWK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WHWK.
Financial health
How did Whitehawk Therapeutics financials performed over time
Whitehawk Therapeutics's total assets has surged by 111% YoY
The total liabilities fell by 40% YoY and by 31% QoQ
The debt is 100% less than the equity
The company's equity has surged by 145% YoY
The debt has plunged by 100% from the previous quarter and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.